细胞白介素-2联合顺铂治疗恶性胸腹水疗效观察  

Efficacy Observation of Interleukin-2 Combined with Cisplatin in the Treatment of Malignant Pleural Effusion

作　　者：李艳艳[1] 王帅[1] 常娜[2] 付文娟[2] 朱晓菊 佟玲[1] 刘素艳[1] 

机构地区：[1]唐山市人民医院药剂科,河北唐山063000 [2]唐山市人民医院肿瘤内科 [3]河北省乐亭县中医院妇产科

出　　处：《中国药师》2017年第5期851-853,共3页China Pharmacist

基　　金：唐山市科技计划项目(编号:15130234a)

摘　　要：目的:探讨细胞白介素-2联合顺铂治疗恶性胸腹水的疗效和安全性。方法:恶性胸腹水患者86例随机分为观察组(44例)和对照组(42例)。对照组采用顺铂治疗,观察组在对照组基础上加用细胞白介素-2。两组疗程均为3周。对两组患者腹水缓解情况、生存质量、生存状况、治疗前后肿瘤标志物水平,以及药品不良反应情况进行评估比较。结果:观察组总体腹水缓解率和有效率均显著高于对照组(P<0.05)。两组患者治疗后癌胚抗原(CEA)、肿瘤标志物CA19-9和糖链抗原(CA450)等水平均较治疗前明显下降(P<0.05),且观察组显著低于对照组(P<0.05)。治疗后,观察组患者生理功能、生理职能、情感职能和躯体疼痛等生存质量维度得分均显著高于对照组(P<0.05)。观察组24个月生存率显著高于对照组(P<0.05)。两组药品不良反应发生率比较,差异无统计学意义(P>0.05)。结论:顺铂联合白介素-2能够有效缓解胸腹水,提高患者生存质量,延长患者生存期。Objective： To investigate the effect and safety of interleukin-2 combined with cisplatin in the treatment of malignant pleural effusion. Methods： Totally 86 patients with malignant pleural effusion were randomly divided into the observation group （44 cases） and the control group （42 eases）. The control group was treated with cisplatin, and the observation group was treated with interleukin -2 additionally. The treatment course was 3 weeks. The ascites relief, quality of life, survival status and tumor markers before and after the treatment, and the adverse drug reactions were compared between the groups. Results： The total ascites remission rate and the effective rate in the observation group were significantly higher than those in the control group （ P 〈 0.05 ）. Compared with those before the treatment, CEA, CA19-9 and CA450 decreased significantly after the treatment in both groups （P 〈 0.05 ）, those in the observation group were significantly lower than those in the control group （P 〈 0.05）. After the treatment, the physiological function, physiological occupation, emotional function, body pain and the other life quality scores in the observation group were significantly higher than those in the control group （P 〈 0.05 ）. The 24-month survival rate in the observation group was significantly higher than that in the control group （ P 〈 0.05 ）. There were no significant differences in adverse drug reactions between the groups （ P 〉 0.05 ）. Conclusion： Interleukin -2 combined with cisplatin can effectively relieve ascites and improve quality of life, which can also prolong the survival time of patients.

关 键 词：细胞白介素-2 顺铂 恶性胸腹水 

分 类 号：R979.1[医药卫生—药品]